Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Summary

Article discusses the potential of Cytokinetics' aficamten drug to strengthen the company's growth prospects in the hypertrophic cardiomyopathy market. No specific clinical data, regulatory decisions, or material announcements are provided in the available text.